Polydeoxyribonucleotide (PDRN) has become an increasingly prominent ingredient in the cosmetics industry, particularly in skincare serums, creams and ampoules.
Traditionally associated with DNA fragments obtained from salmon or trout, PDRN has gained popularity following its use in medical and aesthetic applications. More recently, PDRN-containing ingredients have been incorporated into topical skincare formulations.
As interest in these products continues to grow, cosmetic manufacturers and brand owners must consider their regulatory status under Regulation (EC) No 1223/2009 on cosmetic products.
Important compliance considerations include ingredient identification, appropriate INCI labelling, product safety assessment, substantiation of cosmetic claims and the documentation required before placing products on the European Union market.
The fact that an ingredient is commercially available for cosmetic use does not automatically demonstrate its safety or regulatory compliance.
What Is PDRN and Why Is It Used in Cosmetics?
PDRN (Polydeoxyribonucleotide) refers to DNA-derived materials composed of nucleotide chains or fragments of defined or varying lengths.
Traditional PDRN ingredients are commonly obtained through the extraction, processing and purification of DNA from fish-derived biological materials, particularly salmon or trout.
Other DNA-derived cosmetic ingredients may be produced using plant-based materials or biotechnological processes and marketed using similar terminology.
However, these raw materials are not necessarily chemically identical.
PDRN-containing cosmetic products are commonly marketed in categories such as:
- Facial serums.
- Moisturising creams.
- Skincare ampoules.
- Eye contour products.
- Cosmetic formulations targeting the appearance of skin texture.
- Products addressing the visible signs of ageing.
The performance of a PDRN-containing product depends on the specific raw material, formulation, concentration and intended conditions of use.
Evidence concerning one form of PDRN should not automatically be extrapolated to all cosmetic products containing DNA-derived ingredients.
Is PDRN Allowed in EU Cosmetic Products?
PDRN is not specifically identified by its general commercial name as a prohibited or restricted ingredient in the annexes to Regulation (EC) No 1223/2009.
However, assessing regulatory status solely by searching for the term “PDRN” is not sufficient.
The actual chemical identity, INCI designation, source, manufacturing process and composition of the supplied raw material must be established.
The relevant annexes to the EU Cosmetics Regulation include:
| Annex | Regulatory scope |
| Annex II | Substances prohibited in cosmetic products |
| Annex III | Substances subject to restrictions |
| Annex IV | Permitted colorants |
| Annex V | Permitted preservatives |
| Annex VI | Permitted UV filters |
The absence of a specific entry under the general name PDRN does not constitute regulatory authorisation or evidence of safety.
All applicable requirements must be evaluated for the actual ingredient and the finished cosmetic product.
PDRN and Sodium DNA: Understanding the INCI Relationship
One of the most important regulatory considerations for PDRN-containing cosmetics is the correct identification of the ingredient for labelling purposes.
Sodium DNA is an established INCI name referring to the sodium salt of deoxyribonucleic acid.
It is commonly associated with certain DNA-derived cosmetic raw materials marketed as PDRN.
The European Commission’s CosIng (Cosmetic Ingredient Database) provides information on cosmetic ingredient names and functions.
However, PDRN and Sodium DNA are not necessarily interchangeable terms in every formulation.
PDRN may describe a particular category of DNA fragments or a commercially defined raw material, while Sodium DNA identifies a specific chemical form.
Different DNA-derived raw materials may require different INCI designations depending on their composition and chemical characteristics.
How Should Manufacturers Verify the Correct INCI Name?
Cosmetic companies should request relevant information from raw material suppliers, including:
- Complete ingredient identity.
- Appropriate INCI designation.
- CAS identification, where available.
- Biological origin and manufacturing process.
- Purity and compositional specifications.
- Molecular weight distribution or fragment characteristics.
- Other ingredients, preservatives or carriers present in the supplied material.
- Supporting regulatory documentation.
The final ingredient declaration must reflect the actual composition of the cosmetic product.
An INCI name appearing in CosIng does not mean that the ingredient has been approved or assessed as safe by the European Commission.
CosIng is an informative database and does not replace the legally binding provisions of the EU Cosmetics Regulation.
Topical PDRN vs. Injectable PDRN: What Is the Regulatory Difference?
A key issue in the assessment of PDRN products is the distinction between topical cosmetic applications and products administered by injection.
PDRN has been associated with different medical and aesthetic procedures in various markets.
However, topical skincare products and injectable preparations do not necessarily fall within the same regulatory framework.
Topical PDRN Cosmetics
Creams, serums and similar products intended for application to the skin may be regulated as cosmetics when their intended purpose and claims meet the definition of a cosmetic product under Article 2 of Regulation (EC) No 1223/2009.
Cosmetic purposes include protecting the skin, keeping it in good condition and changing its appearance.
Injectable PDRN Products
Products intended for injection are not classified as conventional cosmetic products under the EU Cosmetics Regulation.
Their regulatory status depends on their intended purpose, mechanism of action and other relevant characteristics.
Such products may fall under medicinal product or other applicable regulatory frameworks.
Can Injectable PDRN Studies Support Claims for Topical Cosmetics?
Clinical studies involving injectable PDRN should not automatically be used as evidence for the efficacy of topical PDRN formulations.
Important differences may include:
- Route of administration.
- Penetration through the skin barrier.
- Molecular size and fragment distribution.
- Ingredient concentration.
- Formulation stability.
- Delivery systems and excipients.
- Intended cosmetic effects.
As a result, claims for a topical cosmetic product should be supported by evidence relevant to that product and its actual conditions of use.
What Claims Can Be Made for PDRN Cosmetic Products?
Claims made for PDRN-containing cosmetic products must comply with Commission Regulation (EU) No 655/2013, which establishes common criteria for cosmetic claims.
These criteria include:
- Legal compliance.
- Truthfulness.
- Evidential support.
- Honesty.
- Fairness.
- Informed decision-making.
Manufacturers should ensure that cosmetic claims used on product packaging, websites, advertising and other marketing materials comply with these principles.
Examples of Cosmetic Claims and Higher-Risk Statements
| Potential cosmetic claims, subject to evidence | Claims requiring particular caution |
| Helps the skin appear smoother | Repairs damaged DNA |
| Supports a hydrated skin appearance | Regenerates damaged tissue |
| Helps improve the appearance of skin texture | Heals wounds |
| Helps maintain skin softness | Treats acne scars |
| Supports a more radiant-looking complexion | Triggers cellular regeneration |
The claims in the first column are not automatically authorised. Their acceptability depends on appropriate substantiation for the finished product.
Statements in the second column may suggest medicinal or therapeutic effects beyond the cosmetic product definition.
Why Must Claims Be Supported by Finished-Product Evidence?
The properties of a cosmetic ingredient do not necessarily establish the performance of the finished formulation.
For example, a study concerning injectable PDRN does not automatically substantiate a claim that a topical serum repairs skin tissue.
Similarly, evidence obtained for one concentration or molecular form of PDRN may not adequately support claims concerning another formulation.
Under Regulation (EU) No 655/2013, cosmetic claims must be supported by adequate and verifiable evidence appropriate to the claimed benefit.
Safety Assessment of PDRN-Containing Cosmetics
Under Articles 3 and 10 of Regulation (EC) No 1223/2009, cosmetic products must be safe for human health under normal or reasonably foreseeable conditions of use.
Before placing a cosmetic product on the EU market, the Responsible Person must ensure that a safety assessment has been performed and a Cosmetic Product Safety Report (CPSR) has been prepared.
For PDRN-containing formulations, the biological origin and characteristics of the ingredient may require particular attention.
Raw Material Origin and Traceability
Manufacturers should establish the source of the PDRN raw material and maintain appropriate traceability documentation.
For animal-derived materials, information on the source organism and manufacturing process may be relevant to the safety assessment.
Purity and Potential Contaminants
The assessment should consider relevant impurities, residual proteins, microbiological contamination and other potential contaminants.
The specific requirements will depend on the raw material and its production process.
Molecular Characteristics
Molecular weight distribution and DNA fragment characteristics may affect the physical and chemical properties of the ingredient.
These characteristics should be appropriately documented where relevant to the safety assessment.
Potential Allergenicity
For fish-derived materials, residual proteins and other potentially allergenic impurities should be considered.
Purification may reduce certain risks, but safety must be supported by appropriate evidence.
Final Product Stability
The stability of the finished cosmetic product should also be evaluated.
Relevant considerations include ingredient stability, microbiological quality, preservation, packaging compatibility and the maintenance of product quality throughout its intended shelf life.
Can PDRN Cosmetics Be Marketed as Vegan?
The answer depends on the origin and composition of the raw materials used.
Cosmetic products containing PDRN derived from salmon, trout or other animal sources should not be marketed as vegan.
However, not every raw material commercially described as PDRN is necessarily animal-derived.
Some DNA-derived materials may be produced from plant-based sources or through biotechnology.
To substantiate a vegan claim, manufacturers should verify:
- Raw material origin.
- Manufacturing processes.
- Processing aids.
- Supplier declarations.
- Other ingredients in the final product.
The absence of animal-derived material in one ingredient does not automatically establish that the entire cosmetic formulation is vegan.
CPSR, PIF and CPNP Requirements for PDRN Cosmetics
PDRN-containing cosmetics must fulfil the applicable obligations under Regulation (EC) No 1223/2009 before being placed on the European Union market.
1. Cosmetic Product Safety Report (CPSR)
The CPSR must address the relevant safety information concerning the finished product and its ingredients.
This includes toxicological data, exposure assessment and other information necessary to demonstrate product safety.
2. Product Information File (PIF)
The Product Information File must contain the documentation required under Article 11, including the product description, CPSR, manufacturing information and proof of the effects claimed for the product, where applicable.
3. EU Responsible Person
Each cosmetic product placed on the EU market must have a designated Responsible Person who ensures compliance with the applicable requirements.
4. Cosmetic Products Notification Portal (CPNP)
The required product information must be submitted through the CPNP before the product is placed on the EU market.
CPNP notification is not equivalent to product approval by the European Commission.
5. Labelling and Ingredient Declaration
The finished product must comply with applicable labelling requirements, including the use of appropriate ingredient names and other mandatory information.
How Should Manufacturers Prepare PDRN Cosmetics for the EU Market?
Companies developing or marketing PDRN-containing cosmetics should take a structured approach to regulatory compliance.
Recommended activities include:
- Verify the ingredient identity: Confirm the actual chemical composition and appropriate INCI designation of the PDRN raw material.
- Establish raw material origin: Determine whether the material is animal-derived, plant-based or produced through biotechnology.
- Review toxicological evidence: Assess whether sufficient safety information is available for the intended use.
- Evaluate finished-product testing: Consider appropriate stability, microbiological and packaging compatibility assessments.
- Review cosmetic claims: Ensure that claims are supported by relevant evidence and do not imply unsubstantiated therapeutic effects.
- Prepare the CPSR and PIF: Complete the required safety and product documentation.
- Complete CPNP notification: Submit the necessary information before placing the product on the EU market.
These measures support both regulatory compliance and the responsible marketing of innovative cosmetic ingredients.
Is PDRN Permitted in EU Cosmetics?
PDRN is an increasingly prominent category of DNA-derived ingredients in the cosmetics industry.
Although PDRN is not specifically prohibited under its general commercial name in the EU Cosmetics Regulation, this does not mean that every PDRN-containing product is automatically safe or compliant.
Correct ingredient identification, appropriate INCI labelling, product safety assessment, substantiated cosmetic claims and complete regulatory documentation are essential.
Manufacturers should be particularly cautious when applying clinical findings from injectable PDRN treatments to topical cosmetic products.
Before entering the EU market, the relevant CPSR, PIF, labelling and CPNP requirements must be fulfilled.
Need Support with PDRN Cosmetics Regulatory Compliance?
Obelis Türkiye supports cosmetic companies in evaluating innovative ingredients, reviewing formulations and INCI declarations, assessing cosmetic claims and managing EU regulatory compliance requirements.
For information about PDRN-containing cosmetics, CPSR and PIF documentation or tailored regulatory assistance, contact us through our website or connect with us on LinkedIn and Instagram.